{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:41:48Z","timestamp":1794962508763,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119300","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:03:04Z","timestamp":1774861384000},"page":"119300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Combining CRISPR\/Cas9-mediated TRAC knockout with mRNA-based CAR expression enables flexible generation of allogeneic CAR T cells"],"prefix":"10.1016","volume":"198","author":[{"given":"Thanyaporn","family":"Buakaew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattapoom","family":"Thaiwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thananya","family":"Inthanachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-6626","authenticated-orcid":false,"given":"Tanapat","family":"Palaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-933X","authenticated-orcid":false,"given":"Koramit","family":"Suppipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-7421","authenticated-orcid":false,"given":"Chatchanan","family":"Ausavarungnirun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-4580","authenticated-orcid":false,"given":"Supannikar","family":"Tawinwung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biopha.2026.119300_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16081599","article-title":"Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies: clinical implications and limitations","volume":"16","author":"Bl\u00fcm","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.biopha.2026.119300_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119300_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119300_bib4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2026.119300_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.omtm.2019.02.008","article-title":"Advancements and obstacles of CRISPR-Cas9 technology in translational research","volume":"13","author":"You","year":"2019","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"issue":"2","key":"10.1016\/j.biopha.2026.119300_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2026.119300_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119300_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"19","key":"10.1016\/j.biopha.2026.119300_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196124","article-title":"Exploring CAR-T cell therapy side effects: mechanisms and management strategies","volume":"12","author":"Zhang","year":"2023","journal-title":"J. Clin. Med"},{"issue":"2","key":"10.1016\/j.biopha.2026.119300_bib10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pr."},{"issue":"19","key":"10.1016\/j.biopha.2026.119300_bib11","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1039\/D1LC00219H","article-title":"mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells","volume":"21","author":"Jayasooriya","year":"2021","journal-title":"Lab Chip"},{"issue":"10","key":"10.1016\/j.biopha.2026.119300_bib12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119300_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119300_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119300_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000188","article-title":"CAR-T cells: future perspectives","volume":"3","author":"Charrot","year":"2019","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.biopha.2026.119300_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ymthe.2019.10.001","article-title":"Simultaneous deletion of endogenous TCR\u03b1\u03b2 for TCR gene therapy creates an improved and safe cellular therapeutic","volume":"28","author":"Morton","year":"2020","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119300_bib17","first-page":"3996","article-title":"T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities","volume":"95","author":"Champlin","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2026.119300_bib18","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/00007890-198906000-00013","article-title":"T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads","volume":"47","author":"Frame","year":"1989","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.biopha.2026.119300_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5030035","article-title":"Role of \u03b1\u03b2 T cell depletion in prevention of graft versus host disease","volume":"5","author":"Abdelhakim","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119300_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155920","article-title":"Engineering off-the-shelf universal CAR T cells: a silver lining in the cloud","volume":"156","author":"Muthuvel","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2026.119300_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jconrel.2022.02.005","article-title":"Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications","volume":"343","author":"Bhattacharjee","year":"2022","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biopha.2026.119300_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119300_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/jmedgenet-2018-105422","article-title":"Applications and advances of CRISPR-Cas9 in cancer immunotherapy","volume":"56","author":"Xia","year":"2019","journal-title":"J. Med. Genet."},{"issue":"4","key":"10.1016\/j.biopha.2026.119300_bib24","article-title":"CRISPR\/Cas9 for cancer therapy: hopes and challenges","volume":"6","author":"Martinez-Lage","year":"2018","journal-title":"Biomed. [Internet]"},{"issue":"21","key":"10.1016\/j.biopha.2026.119300_bib25","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","article-title":"Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma","volume":"28","author":"Meister","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.biopha.2026.119300_bib26","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"7643","key":"10.1016\/j.biopha.2026.119300_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.biopha.2026.119300_bib28","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119300_bib29","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.biopha.2026.119300_bib30","first-page":"5697","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119300_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2026.119300_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"issue":"10","key":"10.1016\/j.biopha.2026.119300_bib33","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1007\/s00415-024-12642-4","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review","volume":"271","author":"Konitsioti","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.biopha.2026.119300_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2026.101584","article-title":"Transient mRNA-Based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy","author":"Inthanachai","year":"2026","journal-title":"Immuno-Oncol. Technol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119300_bib35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41392-025-02512-4","article-title":"Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy","volume":"10","author":"Hu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119300_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cryobiol.2020.07.009","article-title":"The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients","volume":"96","author":"Su","year":"2020","journal-title":"Cryobiology"},{"key":"10.1016\/j.biopha.2026.119300_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.omtm.2022.12.004","article-title":"Cryopreserved anti-CD22 and bispecific anti-CD19\/22 CAR T cells are as effective as freshly infused cells","volume":"28","author":"Dreyzin","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119300_bib38","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","article-title":"Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients","volume":"12","author":"Maschan","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.119300_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/14653249.2011.623691","article-title":"Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-\u03b3 licensing","volume":"14","author":"Fran\u00e7ois","year":"2012","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.biopha.2026.119300_bib40","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/stem.1729","article-title":"Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?","volume":"32","author":"Moll","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.biopha.2026.119300_bib41","article-title":"Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response","volume":"2025","author":"Pham","year":"2025","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.biopha.2026.119300_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqae015","article-title":"Impact of cryopreservation on immune cell metabolism as measured by SCENITH","volume":"6","author":"Luscombe","year":"2025","journal-title":"Oxf. Open Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119300_bib43","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.ymthe.2025.04.006","article-title":"High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing","volume":"33","author":"Cadinanos-Garai","year":"2025","journal-title":"Mol. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:54:41Z","timestamp":1779245681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226003331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"alternative-id":["S0753332226003331"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119300","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining CRISPR\/Cas9-mediated TRAC knockout with mRNA-based CAR expression enables flexible generation of allogeneic CAR T cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119300"}}